Original Article

Immunotherapy Using Autoclaved *L. major* Antigens and *M. vaccae* with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis

*Sh Jamshidi¹, R Avizeh², M Mohebali³, S Bokaie⁴*

¹Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
²Department of Clinical Sciences, Faculty of Veterinary Medicine, Shahid Chamran University, Ahvaz, Iran
³Dept. of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
⁴Department of Food Hygiene, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

(Received 12 Jan 2011; accepted 25 July 2011)

ABSTRACT

**Background:** To evaluate immunotherapy against canine visceral leishmaniasis, *Leishmania major* antigen and heat-killed *Mycobacterium vaccae* (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate.

**Methods:** Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection was carried out in 15 out of 19 dogs using *L. infantum*, isolated from a naturally infected poly-symptomatic dog.

**Results:** All the cases showed positive serologic results by direct agglutination test during 30-60 days following inoculation. In the first group, which was under chemotherapy (Glucantime®), one of the members showed recurrence of the disease despite rapid effect of the therapeutic protocol. Immunotherapy using SRL172 caused complete cleaning of the parasite in group 2, but the speed was less than Glucantime. Immunotherapy using *L. major* antigen combined with *M. vaccae* in group 3 and combine administration of immunotherapy and chemotherapy in group 4 both were with relapsing of one case in each group. Group 5 and 6 were consisted of positive and negative control dogs, respectively.

**Conclusion:** Immunotherapy seems to be an adjuvant in treatment of canine leishmaniasis but it needs more investigation for final confirmation.

**Keywords:** Canine visceral leishmaniasis, Immunotherapy, Glucantime, *Mycobacterium vaccae*

*Corresponding Author: +989121038953; fax: +98216933222; E-mail: shjamshidi@vetmed.ut.ac.ir*
Introduction

Visceral leishmaniasis (VL), one of the most important chronic and systemic zoonosis, caused by a biphasic protozoan belongs to genus *Leishmania* (1). Due to considerable difficulties in eradication of the disease, visceral leishmaniasis is one of the most important parasitic diseases, which are endemic in different parts of Iran. The canidae family especially domestic dogs are the most important sources of *L. infantum* infection for human. There is a large dog population in Iran (7 dogs/100 humans in Meshkin-shahr) and rate of infection may reach to 20% in some villages (2). Canine leishmaniasis in dogs is more resistant to therapy than human leishmaniasis, and only rarely *Leishmania* organisms are eliminated with available drugs. Killing the symptomatic and seropositive dogs is obviously unacceptable to the owners, and it is ineffective because nonsymptomatic dogs and occasionally seronegative dogs are sources of parasite transmission (1). Side effects have been reported following treatment with conventional chemical compounds (pentavalent antimony) and new substitutions such as allopurinol, aminosidine and antifungal drugs (3, 4). Although recurrence of the disease has also been frequent resulting in seeking new treatment protocols, immunotherapy as an efficient and alternative way can help in solving the problem. Gamma interferon, interleukin 12 and liposomal forms of some drugs are new treatment protocols with significant effect on treatment of visceral leishmaniasis (5, 6).

The aim of this interventional study was to determine the effectiveness of immunotherapy in experimental canine visceral leishmaniasis (CVL) in comparison with meglumine antimoniate.

Materials and Methods

Animals

Nineteen mongrel dogs aged 1-3 years were used in this experiment. The dogs were housed in individual cages in small animal hospital, Veterinary Faculty of Tehran University. All dogs appeared healthy, as determined by results of physical examination and normal hemogram. All of them were treated against internal and external parasites. In addition, the dogs were confirmed to be free of *Leishmania* infection using parasitological and serological tests.

Parasite

A symptomatic infected dog, positive by both direct agglutination test (DAT) and ELISA against *Leishmania* infection, was used as the donor source of the inoculum. During the necropsy, visceral leishmaniasis confirmed by observation of hepatosplenomegaly as well as enlargement of the abdominal lymph nodes, and presence of the parasite confirmed by examination of impression smears prepared from lymphoproliferative organs. Using RAPD-PCR technique the isolated parasite was identified as *L. infantum* (7).

Experimental design

Spleen from donor dog was minced to small cubes, macerated in Hank's balanced salt solution in a grinder, and dilution were made to provide the desired number of organisms. Fifteen out of 19 dogs were injected intravenously with 5 ml of the spleen homogenate containing at least $3 \times 10^5$ amastigotes/ml. Infection of the dogs was assessed by collecting bone marrow aspirates, ELISA and DAT. These infected dogs were randomly allocated into five treatment groups.
of three dogs each. Group 1 dogs (Chemotherapy) were received glucantime (Rhone-poulenc Rorer Ltd., France) 100 mg/kg/day, IM for 30 consecutive days. Group 2 dogs (Immunotherapy) were administered intradermally 0.1 ml suspension of heat-killed M. vaccae (SRL172), 3 times in a month intervals containing 10 mg/ml bacterial protein extract. Group 3 dogs (Dual Immunotherapy) were injected intradermally with 0.1 ml autoclaved L. major antigen (ALm was prepared from the promastigotes of L. major (MRHO/IR/76/ER, vaccine, Razi Vaccine & Serum Research Institute, Iran), 3 times monthly in combination with SRL172 as the same dose in group 2. Each ml of autoclaved L. major antigen contained 3.6 mg parasite protein. Group 4 dogs (Immunotherapy & Chemotherapy) were injected with glucantime plus L. major antigen and SRL172 as the same doses in groups 1 and 3. Group 5 dogs (Positive control) were received sterile normal saline in a same volume as glucantime, IM, for 30 consecutive days. One more group comprising four dogs were served as negative control for evaluation of environmental factors and their treatment were performed as group 5.

The animals were monitored for parasite establishment and subsequently for the development of leishmaniasis. This was achieved by routine screening of the dog for classical clinical signs, hematological and serological examinations for ten months after inoculation. Treatments were started two months after infection reconfirmed by serological and parasitological examinations. The animals were clinically examined regularly each day to follow up the potential side effects as well as signs of infection during the study. Blood samples were taken before inoculation and at monthly intervals up to four months after cessation of treatment. The presence of specific antibodies against Leishmania spp. was evaluated monthly by DAT, using the cut off value of 1:320 and above (8). Doubtful results were confirmed by ELISA or Dipstick rK39 rapid tests (9). Four months after the end of treatment protocols, all of the animals were euthanized and samples of bone marrow puncture, spleen, and liver were prepared for parasitological examinations. The mentioned samples underwent Giemsa staining followed by microscopic examination by light microscope with high magnification (× 1000) for the presence of parasite.

**Statistical analysis**
Repeat measure one-way ANOVA test was performed for assess differences between hematological measurements and resistance or susceptibility to anti Leishmania therapy using SPSS software program. The influence of different treatment protocols on serological and parasitological examinations was evaluated using Fisher exact test. Data were considered significant at a $P$ value $< 0.05$.

**Results**
The most common clinical signs in infected animals were skin lesions (13 cases), conjunctivitis (9 cases), and enlargement of popliteal (15 cases) and submandibular lymph nodes (15 cases). Enlargement of the popliteal lymph nodes also happened earlier in the course of the study (after 48-65 days) in comparison with submandibular and prescapular lymph nodes (after 53-75 days). In animals that received chemotherapy, the signs resolved gradually after 45 days, Whereas, this resolution took longer in groups which received immunotherapy with adjuvant (group 2) (70 days), killed parasite antigen with adjuvant (group 3) (85 days) and immunotherapy plus chemotherapy (group 4) (115 days). There were no significant changes in spleen and liver size against lymph nodes following treatment in different groups.
The most important and noticeable hematological changes were reduction in white and red blood cells (Table 2 and 3), PCV and hemoglobin. These factors returned to their normal values following treatment in groups 1 to 4. At the end of the experiment, all of the factors were in normal ranges for every subject except one dog in group 1 that was probably affected by the recurrence of clinical signs, and another one in group 4 that remained positive until the end of the experiment. All of the positive control animals also were shown reduction in hematological parameters until the end of study.

Based on the serological results, 30-60 days following inoculation, all of the animals had positive titers (≥ 1:320). Performance of treatment protocols changed the titers to negative but with varying time courses: group 1 (1 month), 2 (2 months), 3 and 4 (3 months). One of the animal in group 1 encountered increase of the serum titer in period of follow up (4 months after cessation of treatment). In addition, one of the dogs in group 4 remained seropositive in all of the experiment. All of the positive control animals preserved their titers until the end of study and no serum titer was detected in negative control animals.

Results of parasitological examination on liver, spleen, and bone marrow samples for observation of Leishman bodies are depicted in Table 4. Out of the animals in therapeutic groups of 1, 3 and 4, two cases responded to treatment according to parasitological results. Whereas in animals treated only with SRL172, no parasite was detected. Based on Fisher exact test in spite of decrease in parasite population, there was no significant difference between groups 1, 3 and 4 with the control group.

**Table 1:** White blood cell count changes before and following anti-*Leishmania* therapy in different groups of dogs (Mean ± SE)

| Stages     | WBC / µl | Before inoculation | After infection | After cessation of treatment | End of the study |
|------------|----------|-------------------|----------------|------------------------------|------------------|
| Groups     |          |                   |                |                              |                  |
| Group I    | 11300 ± 529\(^{a}\) | 9100 ± 230\(^{a}\) | 11300 ± 378 | 10633 ± 384\(^{a}\) |                  |
| Group II   | 10900 ± 435\(^{a}\) | 8700 ± 288\(^{a}\) | 10900 ± 450 | 10966 ± 371 |                  |
| Group III  | 10666 ± 554\(^{a}\) | 7900 ± 321\(^{a}\) | 10600 ± 458 | 10666 ± 566 |                  |
| Group IV   | 11100 ± 929\(^{a}\) | 8600 ± 665\(^{a}\) | 10700 ± 550 | 10700 ± 642\(^{a}\) |                  |
| Group V    | 11466 ± 788 | 8700 ± 435 | 8466 ± 523 | 8300 ± 642 |                  |
| Group VI   | 10925 ± 436 | 11075 ± 526 | 11125 ± 520 | 11225 ± 558 |                  |

\(^{a}\) Significantly different (P<0.05)
Table 2: Red blood cell count changes before and following anti-Leishmania therapy in different groups of dogs (Mean ± SE)

| Stages                        | Before inoculation | After infection | After cessation of treatment | End of the study |
|-------------------------------|--------------------|----------------|-----------------------------|------------------|
| Groups                        | RBC × 10^6/µl      |                |                             |                  |
| Group I                       | 7.0 ± 0.15^s       | 5.9 ± 0.21^s   | 6.9 ± 0.12                  | 6.6 ± 0.46^s     |
| Group II                      | 7.0 ± 0.17^s       | 5.9 ± 0.06^s   | 7.1 ± 0.10                  | 7.1 ± 0.06       |
| Group III                     | 7.1 ± 0.17^s       | 5.7 ± 0.12^s   | 7.0 ± 0.12                  | 7.0 ± 0.10       |
| Group IV                      | 7.3 ± 0.23^s       | 6.0 ± 0.12^s   | 7.1 ± 0.31                  | 7.2 ± 0.25       |
| Group V                       | 7.3 ± 0.23         | 5.9 ± 0.21     | 5.9 ± 0.12                  | 5.7 ± 0.12       |
| Group VI                      | 7.2 ± 0.14         | 7.2 ± 0.13     | 7.2 ± 0.09                  | 7.3 ± 0.09       |

^s Significantly different (P<0.05)

Table 3: Observation of Leishman bodies from tissues removed at necropsy at the end of study

| Tissue       | Spleen | Liver | Bone marrow |
|--------------|--------|-------|-------------|
| Group        |        |       |             |
| Group I      | 1/3^s  | 1/3   | 1/3         |
| Group II     | 0/3    | 0/3   | 0/3         |
| Group III    | 1/3    | 0/3   | 1/3         |
| Group IV     | 1/3    | 0/3   | 1/3         |
| Group V      | 3/3    | 3/3   | 3/3         |
| Group VI     | 0/4    | 0/4   | 0/4         |

^§ Number of positive/number of tested.
Table 3: Serological results (DAT=>1; 320) of experimental leishmaniasis under treatment with chemical and immunological procedures

| Group   | Before inoculation | After inoculation (month) | Before treatment | During treatment | After treatment |
|---------|--------------------|---------------------------|-----------------|-----------------|----------------|
|         |                    |                           | Before infection | After infection |                |
| Group I | 0/3§               | 1                         | 2               | 3               | 4              |
|         |                    | 1/3                       | 0/3             | 0/3             | 1/3            |
| Group II| 0/3                | 2/3                       | 3/3             | 3/3             | 3/3            |
|         |                    | 3/3                       | 3/3             | 3/3             | 3/3            |
| Group III| 0/3              | 2/3                       | 3/3             | 3/3             | 3/3            |
|         |                    | 3/3                       | 3/3             | 3/3             | 3/3            |
| Group IV| 0/3                | 1/3                       | 3/3             | 3/3             | 3/3            |
|         |                    | 3/3                       | 3/3             | 3/3             | 3/3            |
| Group V | 3/3                | 2/3                       | 3/3             | 3/3             | 3/3            |
|         |                    | 3/3                       | 3/3             | 3/3             | 3/3            |
| Group VI| 0/4                | 0/4                       | 0/4             | 0/4             | 0/4            |
|         |                    | 0/4                       | 0/4             | 0/4             | 0/4            |

§ Number of positive/number of tested

Discussion

In this study, experimental leishmaniasis by intravenous injection of spleen homogenous extract including amastigote form of the parasite was performed for the first time in Iran. Abranches et al. (10) used both forms of the parasite in experimental infection and indicated that amastigote form could induce a stronger humoral immunity and more obvious clinical signs in dogs. Up to now the promastigote form of the parasite, which was acquired from culture, has been used in experimental infection. Induction of experimental infection using this form of parasite is time consuming and rather costly because it must be cultured on enriched medium.

Results of chemotherapy showed that in spite of relatively earlier effect it was not complete. Although the animals became serologically negative (< 320) one month after treatment, infection recurred in one dog four months later, which was confirmed by parasitology. Bergeaud (11) and Melo et al. (12) believed that glucantime have a complete effect on recovery of dogs either in natural or experimental cases. They did not mention their follow up duration. Possibly, in shorter period, the treatment was considered complete. However, in respect to the persistence of parasite in various tissues of affected animals, parasitological examination is highly crucial. Likewise Neogy et al. (13) reported that 37.5% of dogs with visceral leishmaniasis responded parasitologically to chemotherapy. *M. vaccae* had an efficient effect in treatment of canine visceral leishmaniasis. Efficacy of the SRL172 was confirmed previously in the treatment of tuberculosis, psoriasis, allergies, periodontal disorders, and some types of malignancies (14-16). It is said that this adjuvant could change immune pathways from antibody production (Th2) to cellular immunity (Th1) (17). In visceral leishmaniasis both types of immune responses develop and it is the balance of the Th1/Th2 responses that is considered important in controlling parasite replication, disease progression, or a cure. The immunoglobulin response is usually massive in clinical forms, however it not a protective response and can eventually be detrimental. Large amounts of
circulating immune complexes deposition in the walls of blood vessels may cause vasculitis, polyarthritis, uveitis, and glomerulonephritis. There is still controversy about the effectiveness of immunotherapy against visceral leishmaniasis. Whereas some reports denote good effects (18-20), others point some unresponsiveness or even worsening of the signs following immunotherapy (21, 22). Incomplete and slower response in dogs treated with killed parasite antigen combined with adjuvant may be related to genetic resistance of the involved animals, state of the disease or type of used antigen. In this study, the effectiveness of _L. major_ antigen was not evaluated, hence we lack a conclusive statement in this regards and it should be studied with more treatment groups.

The effects of adjuvant and killed parasite antigen combined with glucantime (group 4) were also slow and incomplete. Although there is some reports denote reduction in glucantime dose or its length of use following combination therapy (immunotherapy and chemotherapy) (23, 24) others report lack of complete response (25). In Neogy's study (13), which used double the dose of glucantime the efficacy was 100%. Failure of complete treatment in one of the animals in-group 4 may be due to the incomplete dose or duration of therapy, which certainly calls for more experiments.

In conclusion, immunotherapy in this study against visceral leishmaniasis was performed with the aim of controlling the disease in dogs as one of the most important reservoirs. Use of _M. vaccae_ as an adjuvant in treatment of canine visceral leishmaniasis is the first pertinent experience and primary results are promising. Results of the groups 3 and 4 that were under treatment with killed parasite antigen combined with adjuvant showed that this type of therapy can reduce the number of parasites in experimental form of the disease, but its favorable effects should also be judged in the natural form of the disease.

**Acknowledgments**

Vials of heat-killed _M. Vaccae_ (SRL 172, 10 mg/ml) were kindly provided by SR Pharma Ltd. (London, UK). This study was financially supported by University of Tehran. The authors declare that there is no conflict of interests.

**References**

1. Slappendel RJ, Ferrer L. Leishmaniasis. In: Greene CE, editor. Infectious diseases of the dog and cat. Philadelphia: WB Saunders Co.; 2005. p. 685-698.
2. Mohebali M, Hajjaran H, Hamzavi Y, Mobedi I, Arshi S, Zarei Z, Akhoudi B, Naeini KM, Avizeh R, Fakhar M. Epidemiological aspects of canine visceral leishmaniasis in the Islamic Republic of Iran. Vet Parasitol. 2005; 129(3-4):243-51.
3. Coukell AJ, Brogden RN. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniosis. Drugs. 1998; 55(4):585-612.
4. Oliva G, Gradoni L, Cortese L, Orsini S, Ciaramella P, Scalone A, de Luna R, Perechino A. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniosis. Ann Trop Med Parasitol. 1998; 92(2):165-71.
5. Chapman WL Jr, Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res. 1984; 45(5):1028-30.
6. Murray HW. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J Infect Dis. 1990; 161(5):992-4.
7. Mohebali M, Parsa B, Motazedian MH, Yaghoobi-Ershadi MR, Hajjaran H. Identification of *Leishmania* species from different parts of Iran using a random amplified polymorphic DNA in human, animal reservoirs and vectors. Med J Islamic Rep Irn. 2002; 15(2):243-6.

8. Edrissian GhH, Hajjaran H, Mohebali M, Soleiman Zadeh G, Bokaei S, Anyari A, Sarkissian MT, Kanani A, Nadim A. Application and evaluation of direct agglutination test in sero–diagnosis of visceral leishmaniasis in man and canine reservoirs in Iran. Iran J Med Sci. 1996; 21(2):119-24.

9. Mohebali M, Taran M, Zarei Z. Rapid detection of *Leishmania infantum* infection in dogs: Comparative study using immunochromatographic dipstick rK39 test and direct agglutination. Vet Parasitol. 2004; 121(3-4):239-45.

10. Abranches P, Santos-Gomes G, Rachamim N, Campino L, Schur LF, Jaffe CL. An experimental model for canine visceral leishmaniosis. Parasite Immunol. 1991; 13(5):537-50.

11. Bergeaud P. The contribution of corticotherapy in the treatment of certain forms of canine leishmaniosis: results of a series of forty-three cases. Prat Med Chirurg Anim Comp. 1988; 23(5):121-7.

12. Melo MA, Franca-Silva JC, Azevedo EO, Costa RTDA, Costa CADA, Costa JO, Mayrink W, Genaro O. Treatment of canine visceral leishmaniasis with glucantime plus immunotherapy. Mem Inst Oswaldo Cruz. 1996; 91:44.

13. Neogy AB, Vouldoukis I, da Costa JM, Monjour L. Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis. Vet Parasitol. 1994; 54(4):367-73.

14. Mayo REP, Stanford JL. Double blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97. Trans R Soc Trop Med Hyg. 2000; 94(5):563-8.

15. Balagon MV, Walsh DS, Tan PL, Callona RV, Abalos RM, Tan EV, Fajardo TT, Watson JD, Walsh GP. Improvement in psoriasis after intradermal administration of heat-killed Mycobacterium vaccae. Int J Dermatol. 2000; 39(1):51-8.

16. Breivik T, Rook GAW. Prevaccination with SRL172 (heat-killed Mycobacterium vaccae) inhibits experimental periodontal disease in Wistar rats. Clin Exp Immunol. 2000; 120(3):463-7.

17. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology. 1998; 93(3):307-13.

18. Sharifi I, Efkari AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, Monemi AZ, Dowlati Y, Godol T, Zicker F, Smith PG, Modabber F. Randomised vaccine trial of single dose of killed *leishmania major* plus BCG against anthroponothic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998; 351(9115):1540-3.

19. Pinelli E, Rutten VP, Bruysters M, Moore PF, Ruitenberg EJ. Compensation for decreased expression of B7 molecules on *Leishmania infantum*-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect Immun. 1999; 67(1):237-43.

20. Cabrera M, Blackwell JM, Castes M, Trujillo D, Convit J, Shaw MA. Immunotherapy with live BCG plus heat killed *Leishmania* induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol. 2000; 22(2):73-9.
21. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG. LeIF: a recombinant *Leishmania* protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol. 1998; 161(11):6171-9.

22. Sjolander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant parasite surface antigen 2 from *Leishmania major* induces a Th1 type of immune response but does not protect against infection. Vaccine. 1998; 16(20):2077-84.

23. Everlien H, Hockertz S. Combined liposomal immuno and chemotherapy of visceral leishmaniasis. Arzneimittelforschung. 1999; 49(11):954-61.

24. Van Lunzen J, Kem P, Schmitz J, Brzoska J, Flessenkamper S, Dietrich M. Short term treatment of visceral leishmaniasis of the old world with low dose interferon gamma and pentavalent antimony. Infection. 1993; 21(6):362-6.

25. Melo MA, Franca-Silva JC, Azevedo EO, da Costa RT, da Costa CA, Toledo VPCP, Costa JO, Mayrink W, Genaro O. Therapeutic clinical trial for asymptomatic canine visceral leishmaniosis by the use of glucantime in association with immunotherapy. Mem Inst Oswaldo Cruz. 1996; 91:290.